Michael J. Farrell is the CEO of ResMed Inc., a healthcare company focused on developing innovative solutions for people with sleep apnea and chronic obstructive pulmonary disease. Since taking the helm in 2019, he has guided the company through significant...
Michael J. Farrell is the CEO of ResMed Inc., a healthcare company focused on developing innovative solutions for people with sleep apnea and chronic obstructive pulmonary disease. Since taking the helm in 2019, he has guided the company through significant growth and transformation. In January 2023, he was appointed as the chair of the board of directors, making him a key figure in both leadership roles. Michael's compensation reflects his performance-focused approach, with a total of $1.15 million in 2022, which included salary, bonuses based on specific performance metrics, and other benefits. Notably, he received vested stock tied to long-term performance goals. Under his leadership, ResMed's stock has shown fluctuations, notably peaking at around $142 million in value by the end of 2021 before stabilizing. Michael's tenure is marked by a strong alignment between executive pay and company performance, showing a focus on long-term value creation. His experience in the healthcare field and strategic vision continues to drive ResMed towards greater heights in the industry.